The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NEW GLOBAL CONTRACT

4 Jun 2007 07:00

Byotrol PLC04 June 2007 BYOTROL NEW GLOBAL CONTRACT ANNOUNCEMENT The Directors of Byotrol plc (the "Company") are pleased to be able to report anew global contract that has been secured by the Company. The Company has worked in partnership to develop a range of productsincorporating Byotrol(R) technology for Fellowes Inc, a leading global providerof office accessories and business machines. As a global provider, Fellowes has access to a wide range of disinfectanttechnologies and chose Byotrol for its residual efficacy, ultra low toxicityprofile and broadband action against a wide range of micro-organisms. Fellowes is launching the Virashield(TM) range of products containing Byotrolacross Europe with a global launch planned in the near future. The range, whichincludes wipes and hand protection foam, is designed to help combat the spreadof infections in the workplace. Virashield(TM) offers both residual efficacy ofup to seven days coupled with broad spectrum capability against a wide range oforganisms including viruses such as influenza and avian flu and bacteriaincluding E.coli. Research has shown that a typical office desk harbours up to400 times more bacteria than a typical toilet seat and the residual efficacyoffered by the Virashield range containing Byotrol will help office workerscombat this real and growing risk of infection. The Virashield(TM) range has been extensively tested by both Byotrol andFellowes and the tests have proven the product's efficacy for up to seven daysfollowing application. The range can both remove microbes from surfaces in anoffice environment and keep the surface microbially clean for this period oftime. Byotrol plc Chief Executive David McRobbie said, "We are delighted to havesecured our first contract that will make Byotrol available on a global basisand that a company the size of Fellowes chose Byotrol as its worldwide strategicpartner for this key product launch. There is growing awareness thatmicro-organisms are not just an issue in hospitals and specialist environmentsand that effective cleaning regimes have a role in a wider range of settings." Headquartered in Illinois, USA with subsidiaries in Canada, Benelux, France,Germany, Italy, Poland, Spain, UK, China, Singapore, Japan, Korea and Australia,they have an extensive distribution & export network reaching over 100countries. Fellowes employs more than 2,700 people throughout the world andexpects global sales in excess of $700 million this year. Enquiries: Byotrol plc 0161 277 9518Stephen Falder Deputy Chairman Richard Bell 07825 204 110Finance Director Charles Stanley Securities 020 7149 6457Philip Davies McCann Erickson PR 01625 822540Jim Rothnie Rawlings Financial 01756 770376John Rawlings This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.